Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMA2 in Alzheimer's Disease (COGNIS)
NCT07062198Phase 3Recruiting
- Sponsor
- ScandiBio Therapeutics
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) (2 arms), sponsored by ScandiBio Therapeutics. Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive subscale at 26 weeks. Started Sep 2025; status: recruiting.
02
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07062198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062198.